As demonstrated in Figure 2(b), higher SNHG12 expression level indicated unfavorable RFS in prostate cancer and hepatocellular carcinoma (HR = 1.71, 95%CI 1.05–2.78, p < 0.05). This evidence concerns the gene SNHG12 and prostate carcinoma.